期刊文献+

高效液相色谱-质谱联用法(HPLC-MS/MS)测定CRRT时血浆哌拉西林/他唑巴坦浓度 被引量:1

Determination of plasma piperacillin/tazobactam concentration in CRRT by high performance liquid chromatography-tandem mass spectrometry(HPLC-MS/MS)
下载PDF
导出
摘要 目的建立准确、灵敏的高效液相色谱-质谱联用法(high performance liquid chromatography-mass spectrometry,HPLC-MS/MS)测定持续肾脏替代(continuous renal replacement, CRRT)时人血浆中哌拉西林钠/他唑巴坦钠的浓度。方法选用高、低两种剂量给药,采取单制剂双周期序贯试验设计,对12例行CRRT患者完成哌拉西林/他唑巴坦钠静脉滴注之后,使用HPLC-MS/MS方法同时测定哌拉西林及他唑巴坦的浓度。采用Gemini C18(50mm×3.0 mm,3μm)分析柱;流动相为甲醇:乙腈:水:1 mol/L氨水:甲酸(25∶15∶60∶0.1∶0.05),质谱检测采用电喷雾离子源,多反应离子监测(MRM)模式检测。结果血浆中哌拉西林线性范围为1~100 mg/L,他唑巴坦线性范围为0.5~40.0 mg/L,高、中、低3个浓度日内及日间精密度均小于5%。实测12例行CRRT患者,血药浓度与给药剂量呈相关性。结论高效液相色谱-质谱联用法灵敏度高、特异性好,可以运用于脓毒症患者接受CRRT时血浆哌拉西林/他唑巴坦浓度的测定。 Objective To establish an accurate and sensitive high performance liquid chromatography-mass spectrometry (HPLC-MS/MS) for the determination of piperacillin in human plasma the concentration of sodium/tazobactam sodium during continuous renal replacement(CRRT). Methods The high-dose and low-dose two-dose method were used to design a single-dose two-cycle sequential test. After 12 patients with CRRT were treated with piperacillin/tazobactam sodium intravenously, HPLC -MS/MS was used simultaneously to determine the concentrations of piperacillin and tazobactam. The Gemini C18(50 mm×3.0 mm, 3 μm) analytical column was used. The mobile phase was methanol, acetonitrile, water, 1 mol/L ammonia, formic acid(25:15:60:0.1:0.05). Mass spectrometry was detected using an electrospray ion source and multiple reactive ion monitoring(MRM) mode. Results The linear range of piperacillin in plasma was 1- 100 mg/L, and the linear range of tazobactam was 0.5~40.0 mg/L. The intra-day and inter-day precision of high, medium and low concentrations were less than 5%. The blood concentration of 12 patients who underwent CRRT was correlated with the dose. Conclusion High performance liquid chromatography-mass spectrometry has high sensitivity and specificity, and can be used to determine the plasma concentration of piperacillin/tazobactam in patients with sepsis receiving CRRT.
作者 蔡云 徐丽 CAI Yun;XU Li(Department of Critical Care Medicine, the Second Hospital of Yinzhou District in Ningbo City, Ningbo 315100, China)
出处 《中国现代医生》 2019年第5期37-41,共5页 China Modern Doctor
基金 浙江省宁波市鄞州区农业与社会发展科技计划项目(38)
关键词 哌拉西林钠/他唑巴坦钠 持续肾脏替代治疗 高效液相色谱-质谱联用法 药动学 Piperacillin sodium/tazobactam sodium Continuous renal replacement therapy High performance liquid chromatography-mass spectrometry(HPLC-MS/MS) Pharmacokinetics
  • 相关文献

参考文献8

二级参考文献75

  • 1徐裕海,李桂新,刘谦慧.感染性休克体液复苏治疗后C反应蛋白和降钙素原动态变化的研究[J].大连医科大学学报,2009,31(1):95-97. 被引量:30
  • 2抗菌药物临床应用指导原则[J].中华医学杂志,2004,84(22):1857-1862. 被引量:203
  • 3袁壮,马沛然,邓力,方鹤松,卢競,江载芳,陈贤楠,陆权,张乾忠,张灵恩,范永琛,洪建国,胡仪吉,胡皓夫,赵祥文,赵顺英,耿荣,夏经,曹玲,鲁继荣,傅文永.50年来小儿肺炎诊治策略的变迁[J].中国实用儿科杂志,2006,21(12):881-908. 被引量:159
  • 4严静.成人严重感染与感染性休克血流动力学监测与支持指南(2006)[J].中国实用外科杂志,2007,27(1):7-13. 被引量:132
  • 5Michel MS,Trojan L,Rassweiler JJ,et al.Complications in percutaneous nephrolithotomy.Eur Urol,2007,51:899-906.
  • 6Zanetti G,Paparella S,Trinchieri A,et al.Infections and urolithiasis:current clinical evidence in prophylaxis and antibiotic therapy.Arch Ital Urol Androl,2008,80:5-12.
  • 7Gehring H,Nahm W,Zimmermann K,et al.Irrigating fluid absorption during percutaneous nephrolithotripsy.Acta Anaesthesiol Scand,1999,43:316-321.
  • 8Tefekli A,Ali Karadag M,Tepeler K.Classification of percutaneous nephrolithotomy complications using the modified clavien grading system:looking for a standard.Eur Urol,2008,53:184-190.
  • 9Oka T,Hara T,Miyake O,et al.A study on bacteria within stones in urolithiasis.Hinyokika Kiyo,1989,35:1469-1474.
  • 10Wagenlehner FM,Weidner W,Naber KG.Pharmacokinetic characteristics of antimicrobials and optimal treatment of urosepsis.Clin Pharmacokinet,2007,46:291-305.

共引文献74

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部